 |
dabrafenib and trametinib |
|---|---|
| Trade Name | Mekinist |
| Orphan Indication | Patients with BRAF mutation positive non-small cell lung cancer |
| USA Market Approval | USA |
| USA Designation Date | 2015-10-29 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 |
